Summary
Common Side Effects
Important Context: All side effect rates below are from Phase 2 and Phase 3 clinical trials in Chinese populations. These are typical for the dual GLP-1/glucagon agonist class and are generally mild to moderate in severity. Notably, mazdutide shows lower discontinuation rates than other GLP-1 medications despite similar GI event frequencies.
Diarrhea
Decreased Appetite
Nausea
Vomiting
Hypoglycemia (Low Blood Sugar)
Increased Heart Rate
Timeline
Understanding the Pattern
Knowing when to expect side effects can help you prepare and manage them effectively. Most gastrointestinal side effects follow a predictable pattern based on dose escalation. Clinical trial data shows GI symptoms are "transient" and occur "mainly during dose escalation."
Typical Side Effect Progression
Weeks 1-4: Initial Dose (3 mg)
What to expect: Diarrhea, nausea, or decreased appetite may occur as your body adjusts to the medication. These are typically mild to moderate.
Management tip: Start with bland foods, stay hydrated, and give your body time to adapt. Most symptoms improve within 2-3 weeks.
Weeks 5-8: First Dose Increase (4.5 mg)
What to expect: GI side effects may temporarily increase again as the dose rises. Diarrhea is most common at this dose (41% in Phase 2).
Management tip: Return to eating smaller, frequent meals. Side effects usually peak in the first week after dose increase, then improve.
Weeks 9-12: Maintenance Dose (6 mg)
What to expect: Your body may adapt more quickly this time. Diarrhea frequency decreases to 29% at this dose in Phase 2 trials.
Management tip: Use strategies that worked during earlier dose increases. GI symptoms should be decreasing overall by this point.
Weeks 13+: Long-Term Maintenance
What to expect: Side effects should be at their lowest as your body has fully adapted. Most people tolerate the maintenance dose well—this is reflected in mazdutide's exceptionally low 0.5% discontinuation rate.
Management tip: If GI side effects persist beyond 8 weeks on maintenance dose, discuss with your doctor whether staying at a lower dose might be appropriate.
Key Takeaway: Side effects are not constant. They peak during dose escalation and typically improve 2-4 weeks after each dose increase. Clinical trials confirm GI symptoms "decreased over time." If you can manage the initial weeks, tolerability usually improves significantly over time.
Mechanism
How Mazdutide Works
Mazdutide is the world's first approved dual GLP-1/glucagon receptor agonist. It combines two mechanisms: GLP-1 receptor activation (appetite suppression, slowed gastric emptying) + glucagon receptor activation (increased energy expenditure, fat burning). While this dual approach enhances metabolic effects, it also explains the side effect profile.
The Connection Between How It Works and Side Effects
GLP-1 Mechanism: Slowed Gastric Emptying
What it does: The GLP-1 component slows the rate at which food moves from your stomach to your intestines. This helps you feel full longer and reduces appetite.
Side effect connection: Food staying in your stomach longer can cause nausea, bloating, decreased appetite, and feeling overly full after small meals.
Why it improves: Your digestive system gradually adapts to the slower emptying rate over 4-8 weeks.
Glucagon Mechanism: Increased GI Motility
What it does: The glucagon component increases metabolic rate and fat oxidation, but it can also stimulate intestinal motility.
Side effect connection: Enhanced gut motility explains why diarrhea is mazdutide's most common side effect (29-41%), higher than other GLP-1 agonists. This is the trade-off for enhanced fat burning.
Why it improves: Your gut's nervous system adjusts to the new signaling pattern over time, restoring more balanced motility.
Glucagon Mechanism: Heart Rate Increase
What it does: Glucagon receptor activation increases heart rate and cardiac output as part of its metabolic stimulation effects.
Side effect connection: Heart rate increases of 11-17 bpm were observed in Phase 1b trials. This is a known glucagon effect seen with all dual agonists.
Why it's tolerated: The heart rate increase is generally mild and asymptomatic. Most patients adapt without noticing symptoms.
Class Effect: The GLP-1 component's side effects (nausea, vomiting, decreased appetite) are consistent with all GLP-1 receptor agonists. The diarrhea and heart rate effects are more specific to the glucagon component, representing the trade-off for enhanced metabolic benefits. Despite these effects, mazdutide's 0.5% discontinuation rate suggests exceptional real-world tolerability.
FAQs
Mazdutide's side effect profile is similar to tirzepatide but with a key difference: diarrhea is more common (29-41% vs ~17-22% for tirzepatide), while nausea rates are similar (22-25%). However, mazdutide's standout feature is its exceptionally low discontinuation rate (0.5-1.5%) compared to tirzepatide (4-6%). This suggests that despite higher diarrhea rates, mazdutide is better tolerated overall.
Mazdutide's glucagon receptor activation contributes to increased intestinal motility, which explains the higher diarrhea rates compared to pure GLP-1 agonists like semaglutide. This is the trade-off for enhanced fat burning and metabolic effects. The good news: diarrhea is typically mild-to-moderate, transient, and rarely leads to treatment discontinuation.
The heart rate increase (11-17 bpm in Phase 1b trials) is a known effect of glucagon receptor activation. For most healthy individuals, this is not clinically significant and most patients don't notice it. However, if you have a history of heart rhythm problems, uncontrolled hypertension, or heart disease, discuss this with your doctor before starting mazdutide. Your doctor may recommend baseline ECG monitoring.
Most gastrointestinal side effects peak during dose escalation (first 1-4 weeks at each dose level) and improve significantly within 4-8 weeks as your body adapts. Clinical trials describe GI symptoms as "transient" and note they "decreased over time." By the maintenance dose phase, most people tolerate mazdutide very well—reflected in the remarkably low 0.5% discontinuation rate.
Yes, mazdutide has been studied in people with type 2 diabetes (DREAMS trials). Hypoglycemia was dose-dependent (6-16%) but all events were mild (Grade 1-2) with no severe hypoglycemia reported. If you're on insulin or sulfonylureas, your doctor may need to reduce those doses when starting mazdutide to prevent low blood sugar. Monitor your glucose regularly during dose escalation.
This is mazdutide's most impressive differentiator. Despite having similar or higher GI event frequencies, the Phase 2 diabetes trial reported zero discontinuations due to GI adverse events, and GLORY-1 showed only 0.5% discontinuation vs 1.0% with placebo. The likely explanation: side effects may be frequent but are typically mild and well-managed, and the medication's efficacy (up to 24.8% weight loss) motivates patients to continue treatment.
Sources
- Zhang P, et al. "Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight." New England Journal of Medicine. 2025. Link
- Cheng M, et al. "Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial." Diabetes Care. 2024;47(1):160-169. Link
- Wang Z, et al. "Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial." eClinicalMedicine. 2022;53:101643. Link
- Innovent Biologics. "Phase 3 Clinical Study of Mazdutide in Chinese Adults with Overweight or Obesity (GLORY-1) Published in The New England Journal of Medicine (NEJM)." PR Newswire. May 2025. Link
- Innovent Biologics. "Head-to-head Superiority over Dulaglutide: Innovent's Phase 3 Clinical Trial DREAMS-2 of Mazdutide in Chinese Patients with Type 2 Diabetes were Orally Presented at EASD 2024." PR Newswire. September 2024. Link
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387:205-216. (For comparison data) Link
Last updated October 6, 2026
Disclaimer
The information on this page is for educational and informational purposes only and is not intended as medical advice. Honest Care does not provide medical diagnosis, treatment, or individualized recommendations. Always seek the advice of your physician or other qualified healthcare professional regarding any medical condition or treatment.
While this content has been reviewed for accuracy and balance, new evidence may emerge after publication. Drug availability, indications, and insurance coverage can change over time. Honest Care makes no warranties as to completeness or currentness of the information and is not responsible for decisions made based on this content.